Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
ViiV Healthcare presents positive data from first-ever implementation research study on how best to integrate an investigational once-monthly injectable HIV treatment in US healthcare practices
Findings presented showed healthcare providers perceived implementation of the treatment as feasible and appropriate for people with HIV.
-
ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available
ViiV today announced that the US FDA has approved Rukobia (fostemsavir), 600 mg extended-release tablets.
-
ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual)
ViiV Healthcare will present over 20 abstracts during next week at the 23rd International AIDS Conference (AIDS 2020: Virtual), 6-10 July.
-
GSK receives first regulatory approval for Duvroq (daprodustat) in Japan for patients with anaemia due to chronic kidney disease
Approval marks a significant step in GSK’s global efforts to help patients with anaemia due to chronic kidney disease (CKD).
-
GSK announces FDA Advisory Committee meeting to review belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma
GSK announces FDA Advisory Committee meeting to review belantamab mafodotin
-
GSK COVID-19 vaccine development collaboration with Clover Biopharmaceuticals begins clinical trials
Clover Biopharmaceuticals initiates phase 1 study using GSK pandemic adjuvant in combination with COVID-19 vaccine candidate SCB-2019
-
GSK prices $280,336,000 Senior Notes Due 2023 Exchangeable into Theravance Biopharma Ordinary Shares
GSK prices $280,336,000 Senior Notes Due 2023 Exchangeable into Theravance Biopharma Ordinary Shares
-
GSK announces Proposed Unregistered Offering of Senior Notes Exchangeable into Theravance Biopharma Ordinary Shares
GSK announces Proposed Unregistered Offering of Senior Notes Exchangeable into Theravance Biopharma Ordinary Shares
-
IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology
IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology
-
ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV
ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir.
-
GSK announces new data presentations from the DREAMM programme exploring investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma
16 presentations, including new analyses from the pivotal DREAMM-2 study and initial results from the DREAMM-4 study
-
GSK announces intention to produce 1 billion doses of pandemic vaccine adjuvant in 2021 to support multiple COVID-19 vaccine collaborations
Announcement follows completion of global manufacturing review and decision to invest in expanded manufacturing capacity
-
DREAMM-2 and DREAMM-6 data at ASCO reinforce the potential of GSK’s investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma
13-month update on the DREAMM-2 study shows median overall survival of 13.7 months and median duration of response of 11 months
-
FDA grants priority review of Nucala for patients with Hypereosinophilic Syndrome (HES)
An approval would give Nucala a third indication in an eosinophil-driven disease
-
GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio
Samsung Biologics will provide GSK with additional capacity for large-scale biopharmaceutical product manufacturing.
-
GSK highlights scientific innovation and advances in its growing oncology portfolio at ASCO 2020
26 abstracts across 8 tumour types, advancing GSK’s goal of maximising outcomes for patients
-
Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP
Interim analysis of the HIV Prevention Trials Network (HPTN) 083 study.
-
FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status
Zejula is the only oral monotherapy available as first-line maintenance treatment for women regardless of BRCA mutational status
-
GSK delivers strong Q1: sales £9.1 billion +19% AER, +19% CER (Proforma +10% CER*)
GSK delivers strong Q1: sales £9.1 billion +19% AER, +19% CER (Proforma +10% CER*)
-
GSK presents new data from the GARNET study demonstrating potential of dostarlimab to treat a subset of women with recurrent or advanced endometrial cancer
Data accepted as a late-breaking abstract and presented as a webinar as part of the Society of Gynecologic Oncology 2020 virtual congress
